Related references
Note: Only part of the references are listed.Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily
J. H. Best et al.
DIABETIC MEDICINE (2009)
Rasch analysis informed the development of a classification system for a diabetes-specific preference-based measure of health
Murali Sundaram et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm
J. Green et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
Tina Vilsboll et al.
DIABETES CARE (2007)
Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes
Kristina Secnik Boye et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2006)
GLP-1 based therapy for type 2 diabetes
DK Arulmozhi et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes
RE Davis et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Measurement of health-related QOL in diabetes mellitus
K Watkins et al.
PHARMACOECONOMICS (2004)
Valuing health-related quality of life in diabetes
JT Coffey et al.
DIABETES CARE (2002)
Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial
S Amiel et al.
BRITISH MEDICAL JOURNAL (2002)
Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes
WK Redekop et al.
DIABETES CARE (2002)
Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes
E Witthaus et al.
DIABETIC MEDICINE (2001)